News

How new agents, improved study outcomes, and priority on diagnosis has bettered the state of dermatologic care.

A study from investigators in Europe found the CCS, ACC/AHA, and NICE guidelines for statin use may be more effective at preventing ASCVD events than ESC/EAS or USPSTF guidelines.

Novartis announced the ongoing Phase 3 PREVENT trial examining use of secukinumab in patients with non-radiographic axial spondyloarthritis has met its primary endpoint of ASAS40.

Its approval was based on findings from the limited assessment of pediatric patients in PANORAMA-HF, showing reduction of a cardiovascular biomarker.

In a review of chronic kidney disease, investigators suggest a variety of screening and risk reduction measures.

An expert with the American Lung Association will lead discussion on one of the greatest drivers of death in the US.

A recent study of pregnancies from the Quebec Pregnancy Cohort found use of antidepressants during pregnancy was linked to an increased rate of gestational diabetes mellitus in an analysis that included more than 200,000 women from 1998 to 2015.

The challenge will bring together providers, institutions, patients, payers, and researchers from across the healthcare ecosystem with the goal of better understanding pain points in healthcare.

The investigative ICS/LAMA/LABA inhaler therapy reported positive findings from its phase 3 ETHOS trial in August, though the results were not included in the FDA application.

Sheetal Desai, MD, AWARE investigator and assistant clinical professor of medicine at UC Irvine, discusses full 52-week results of study comparing 2 popular rheumatoid arthritis patients and what the observed safety profile means from a patient-centered perspective.

The 12-year update highlights promising novel therapy classes, and sets disparities between pediatric and adult chronic cough treatment.

From immunotherapy to biologics, the field of allergy pharmacotherapy is looking promising.

Results from the TRIMARAN and TRIGGER trials show significant benefits for 2 different doses of the ICS/LABA/LAMA combination.

The diabetes management and adult health specialist reacts to the SGLT2 inhibitor's newest indication.

Aaron Broadwell, MD, rheumatologist and AWARE investigator, discusses his interpretation of the full 52-week results of the trial, which examined golimumab and infliximab in patients with rheumatoid arthritis in a real-world setting.

The SGLT2 inhibitor from Janssen has shown significant benefit for reducing progression to end-stage kidney disease, as well as risk for major adverse cardiovascular events.

How can physicians and specialists navigate testing options and potential risk factors to ensure patients are diagnosed and treated expediently and accurately?

A new study from ERS showed the technological material common among training athletes could help physicians monitor patients with COPD.

There has been significant changes in understanding surrounding food allergy testing. What do parents need to know?

Sheetal Desai, MD, a rheumatologist and investigator of the ongoing AWARE trial, discusses her clinical takeaways from the 52-week results and the importance of real-world evidence.

AWARE Trial investigator Aaron Broadwell, MD, discusses what new data was presented during CCR West and how it differed from a previously presented interim analysis.

The indication for the add-on monoclonal antibody makes it the first approved therapy for children with the rare vasculitis conditions.

A new study from the ERS International Congress shows a trio of air pollutants are associated with significant increases in all-cause infant mortality in the UK.

Investigators deem phase 2 study using pimavanserin to treat major depressive disorder a success.

The FDA approves Mavyret as an 8-week treatment for all genotypes of HCV with compensated cirrhosis.

The approval is based on findings showing patients on the drug plus VTd had a 53% reduction in risk of disease progression or death, compared to lone VTd.

In an extensive review of 18 cohort studies, investigators connect dietary patterns with chronic kidney disease incidence rates.

The Proclaim XR recharge-free system provides relieve through a low-dose proprietary BurstDR stimulation waveform, which mimics natural brainwave patterns that change pain signals traveling from the spinal cord to the brain.

A comparative assessment of step-up therapy strategies for black patients with inadequately controlled asthma showed varying responses.

The AGA-approved guidelines call for a variety of different testing to better diagnose IBS-D in adults.